The main purpose of the study is to compare the effects of three different types of RAAS blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.
Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) is the main target of therapy to reduces both proteinuria and the rate of decline of the glomerular filtration rate in non-diabetic chronic renal diseases. Despite recent progress, however, there is still no optimal therapy that can stop the progression of these nephropathies. Therefore, it is necessary to optimize such treatment for further improving renal outcome. The aim of the present study was to compare the effects of three different types of RAAS blockade: (1) mineralocorticoid receptor blocker (MRB) + angiotensin receptor antagonist (ARA); (2) direct renin inhibitor (DRI) + ARA and (3) double maximal dose of ARA on 24 hours proteinuria in patients with non-diabetic chronic kidney disease
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
20
aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
Difference in urinary albumin-to-creatinine ratio (UACR) between treatment arms
changes of UACR
Time frame: baseline and the end of 8 week treatments
Difference in transforming growth factor beta (TGF-beta) between treatment arms
Changes of urinary excretion of transforming growth factor beta (TGF-beta)
Time frame: baseline and the end of 8 week treatments
Difference in serum potassium and creatinine between treatment arms
Time frame: baseline and the end of 8 week treatments
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.